Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15304989,AUC,"Mono-PEG2k-sCT exhibited significantly increased AUC (20,638 vs. 3,650 ng.min/ml), tmax (520 vs. 77 min), and t1/2,lambdaz (923 vs. 199 min) compared with unmodified sCT.",Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304989/),[min·ng] / [ml],"20,638",651,DB00017,Salmon Calcitonin
,15304989,AUC,"Mono-PEG2k-sCT exhibited significantly increased AUC (20,638 vs. 3,650 ng.min/ml), tmax (520 vs. 77 min), and t1/2,lambdaz (923 vs. 199 min) compared with unmodified sCT.",Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304989/),[min·ng] / [ml],"3,650",652,DB00017,Salmon Calcitonin
,15304989,tmax,"Mono-PEG2k-sCT exhibited significantly increased AUC (20,638 vs. 3,650 ng.min/ml), tmax (520 vs. 77 min), and t1/2,lambdaz (923 vs. 199 min) compared with unmodified sCT.",Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304989/),min,520,653,DB00017,Salmon Calcitonin
,15304989,tmax,"Mono-PEG2k-sCT exhibited significantly increased AUC (20,638 vs. 3,650 ng.min/ml), tmax (520 vs. 77 min), and t1/2,lambdaz (923 vs. 199 min) compared with unmodified sCT.",Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304989/),min,77,654,DB00017,Salmon Calcitonin
,15304989,"t1/2,lambdaz","Mono-PEG2k-sCT exhibited significantly increased AUC (20,638 vs. 3,650 ng.min/ml), tmax (520 vs. 77 min), and t1/2,lambdaz (923 vs. 199 min) compared with unmodified sCT.",Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304989/),min,923,655,DB00017,Salmon Calcitonin
,15304989,"t1/2,lambdaz","Mono-PEG2k-sCT exhibited significantly increased AUC (20,638 vs. 3,650 ng.min/ml), tmax (520 vs. 77 min), and t1/2,lambdaz (923 vs. 199 min) compared with unmodified sCT.",Nasal absorption and pharmacokinetic disposition of salmon calcitonin modified with low molecular weight polyethylene glycol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304989/),min,199,656,DB00017,Salmon Calcitonin
,8990225,detection limit,"This combination of antibodies resulted in an assay that was three to four times more sensitive than the previous IFMA, with a detection limit of 0.3 pmol/L serum.",Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8990225/),[pM] / [l],0.3,8803,DB00017,Salmon Calcitonin
,8990225,recoveries,"Intact SCT 1-32 was detected by the assay (recoveries 94-96%), but not the fragments SCT 1-11 and SCT 10-32 or human calcitonin.",Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8990225/),%,94-96,8804,DB00017,Salmon Calcitonin
,8990225,peak serum concentrations,"Pharmacokinetic studies of SCT, 100 IU administered intramuscularly to 10 men, indicated peak serum concentrations of 32-128 pmol/L within 10-20 min with apparent half-life of 56+/-18 min (mean+/-SD).",Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8990225/),[pM] / [l],32-128,8805,DB00017,Salmon Calcitonin
,8990225,apparent half-life,"Pharmacokinetic studies of SCT, 100 IU administered intramuscularly to 10 men, indicated peak serum concentrations of 32-128 pmol/L within 10-20 min with apparent half-life of 56+/-18 min (mean+/-SD).",Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8990225/),min,56,8806,DB00017,Salmon Calcitonin
,1743807,bioavailabilities,The pharmacodynamic bioavailabilities for total and ionized calcium of the 100 IU suppository and the 50 IU intramuscularly were 106% and 60%.,Hypocalcemic effects of rectal and intramuscular administration of synthetic salmon calcitonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743807/),%,106,11167,DB00017,Salmon Calcitonin
,1743807,bioavailabilities,The pharmacodynamic bioavailabilities for total and ionized calcium of the 100 IU suppository and the 50 IU intramuscularly were 106% and 60%.,Hypocalcemic effects of rectal and intramuscular administration of synthetic salmon calcitonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743807/),%,60,11168,DB00017,Salmon Calcitonin
,10231888,molecular,"The molecular weights of mono-PEG-sCT and di-PEG-sCT were determined to be 16,094 and 29,077 Da, respectively.",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),da,"16,094",14000,DB00017,Salmon Calcitonin
,10231888,molecular,"The molecular weights of mono-PEG-sCT and di-PEG-sCT were determined to be 16,094 and 29,077 Da, respectively.",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),da,"29,077",14001,DB00017,Salmon Calcitonin
,10231888,circulating half-lives,"In clearance studies in the rat, PEGylated sCTs had significantly longer circulating half-lives than the intact sCT (11.2 min for mono-PEG-sCT and 54.0 min for di-PEG-sCT versus 4.7 min for intact sCT).",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),min,11.2,14002,DB00017,Salmon Calcitonin
,10231888,circulating half-lives,"In clearance studies in the rat, PEGylated sCTs had significantly longer circulating half-lives than the intact sCT (11.2 min for mono-PEG-sCT and 54.0 min for di-PEG-sCT versus 4.7 min for intact sCT).",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),min,54.0,14003,DB00017,Salmon Calcitonin
,10231888,circulating half-lives,"In clearance studies in the rat, PEGylated sCTs had significantly longer circulating half-lives than the intact sCT (11.2 min for mono-PEG-sCT and 54.0 min for di-PEG-sCT versus 4.7 min for intact sCT).",Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10231888/),min,4.7,14004,DB00017,Salmon Calcitonin
,21882837,T(max),"L-PEG and B-PEG-based microparticles were able to increase T(max) to 20 ± 1 min and 18 ± 8 min, respectively.",Evaluation of HPβCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882837/),min,20,28798,DB00017,Salmon Calcitonin
,21882837,T(max),"L-PEG and B-PEG-based microparticles were able to increase T(max) to 20 ± 1 min and 18 ± 8 min, respectively.",Evaluation of HPβCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882837/),min,18,28799,DB00017,Salmon Calcitonin
,9850187,detection limit,The practical detection limit of ECT was 0.15 pg (44 amol)/50 microl of sample and 3 pg/ml as the concentration.,Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850187/),pg,0.15,34793,DB00017,Salmon Calcitonin
,9850187,area underthe serum concentration-time curve (AUC),"The pharmacokinetic parameters of the intranasal ECT (n = 6) thus estimated were as follows: the area underthe serum concentration-time curve (AUC) = 2,570 +/- 1,650 (SD) pg x min/ml, and the maximal concentration (Cmax) = 60 +/- 25 (SD) pg/ml with the maximal time (Tmax) = 17.5 +/- 6.9 (SD) min, when the AUC for the intramuscular ECT (n = 9) = 9,460 +/- 5,870 (SD) pg x min/ml and the Cmax = 165 +/- 79 (SD) pg/ml with the Tmax = 16.1 +/- 4.2 (SD) min.",Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850187/),[min·pg] / [ml],"2,570",34794,DB00017,Salmon Calcitonin
,9850187,maximal concentration (Cmax),"The pharmacokinetic parameters of the intranasal ECT (n = 6) thus estimated were as follows: the area underthe serum concentration-time curve (AUC) = 2,570 +/- 1,650 (SD) pg x min/ml, and the maximal concentration (Cmax) = 60 +/- 25 (SD) pg/ml with the maximal time (Tmax) = 17.5 +/- 6.9 (SD) min, when the AUC for the intramuscular ECT (n = 9) = 9,460 +/- 5,870 (SD) pg x min/ml and the Cmax = 165 +/- 79 (SD) pg/ml with the Tmax = 16.1 +/- 4.2 (SD) min.",Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850187/),[pg] / [ml],60,34795,DB00017,Salmon Calcitonin
,9850187,maximal time (Tmax),"The pharmacokinetic parameters of the intranasal ECT (n = 6) thus estimated were as follows: the area underthe serum concentration-time curve (AUC) = 2,570 +/- 1,650 (SD) pg x min/ml, and the maximal concentration (Cmax) = 60 +/- 25 (SD) pg/ml with the maximal time (Tmax) = 17.5 +/- 6.9 (SD) min, when the AUC for the intramuscular ECT (n = 9) = 9,460 +/- 5,870 (SD) pg x min/ml and the Cmax = 165 +/- 79 (SD) pg/ml with the Tmax = 16.1 +/- 4.2 (SD) min.",Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850187/),min,17.5,34796,DB00017,Salmon Calcitonin
,9850187,AUC,"The pharmacokinetic parameters of the intranasal ECT (n = 6) thus estimated were as follows: the area underthe serum concentration-time curve (AUC) = 2,570 +/- 1,650 (SD) pg x min/ml, and the maximal concentration (Cmax) = 60 +/- 25 (SD) pg/ml with the maximal time (Tmax) = 17.5 +/- 6.9 (SD) min, when the AUC for the intramuscular ECT (n = 9) = 9,460 +/- 5,870 (SD) pg x min/ml and the Cmax = 165 +/- 79 (SD) pg/ml with the Tmax = 16.1 +/- 4.2 (SD) min.",Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850187/),[min·pg] / [ml],"9,460",34797,DB00017,Salmon Calcitonin
,9850187,Cmax,"The pharmacokinetic parameters of the intranasal ECT (n = 6) thus estimated were as follows: the area underthe serum concentration-time curve (AUC) = 2,570 +/- 1,650 (SD) pg x min/ml, and the maximal concentration (Cmax) = 60 +/- 25 (SD) pg/ml with the maximal time (Tmax) = 17.5 +/- 6.9 (SD) min, when the AUC for the intramuscular ECT (n = 9) = 9,460 +/- 5,870 (SD) pg x min/ml and the Cmax = 165 +/- 79 (SD) pg/ml with the Tmax = 16.1 +/- 4.2 (SD) min.",Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850187/),[pg] / [ml],165,34798,DB00017,Salmon Calcitonin
,9850187,Tmax,"The pharmacokinetic parameters of the intranasal ECT (n = 6) thus estimated were as follows: the area underthe serum concentration-time curve (AUC) = 2,570 +/- 1,650 (SD) pg x min/ml, and the maximal concentration (Cmax) = 60 +/- 25 (SD) pg/ml with the maximal time (Tmax) = 17.5 +/- 6.9 (SD) min, when the AUC for the intramuscular ECT (n = 9) = 9,460 +/- 5,870 (SD) pg x min/ml and the Cmax = 165 +/- 79 (SD) pg/ml with the Tmax = 16.1 +/- 4.2 (SD) min.",Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850187/),min,16.1,34799,DB00017,Salmon Calcitonin
,16176019,absolute p,The relative pharmacological bioavailability of the intracolonically administered Lys18-PEG(2K)-sCT was 2.1-fold higher than sCT and the absolute pharmacological bioavailability was 73.59% of i.v.-injected sCT in an 8-hr period.,Oral delivery of mono-PEGylated sCT (Lys18) in rats: regional difference in stability and hypocalcemic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176019/),%,73.59,35153,DB00017,Salmon Calcitonin
,15618755,MRT,The pharmacokinetics of sCT described by a conventional two-compartment model showed the extremely rapid elimination of sCT from plasma (MRT; 6.86 min).,Estimation of bioavailability of salmon calcitonin from the hypocalcemic effect in rats (I): pharmacokinetic-pharmacodynamic modeling based on the endogenous Ca regulatory system. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618755/),min,6.86,47305,DB00017,Salmon Calcitonin
,12162502,absolute bioavailability,"SCT was reliably absorbed from the oral formulation, with an absolute bioavailability of 0.5-1.4%, depending on the dose.",Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162502/),%,0.5-1.4,59579,DB00017,Salmon Calcitonin
,11145145,systemic clearance,"Di-PEG-sCT exhibited significantly reduced systemic clearance (2.3 vs. 11.1 ml/min/kg) and steady-state volume of distribution (229.9 vs. 603.1 ml/kg), while mono-PEG-sCT showed a prolonged elimination half-life (189.1 min vs. 59.8 min) compared with unmodified sCT.",Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145145/),[ml] / [kg·min],2.3,61675,DB00017,Salmon Calcitonin
,11145145,systemic clearance,"Di-PEG-sCT exhibited significantly reduced systemic clearance (2.3 vs. 11.1 ml/min/kg) and steady-state volume of distribution (229.9 vs. 603.1 ml/kg), while mono-PEG-sCT showed a prolonged elimination half-life (189.1 min vs. 59.8 min) compared with unmodified sCT.",Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145145/),[ml] / [kg·min],11.1,61676,DB00017,Salmon Calcitonin
,11145145,steady-state volume of distribution,"Di-PEG-sCT exhibited significantly reduced systemic clearance (2.3 vs. 11.1 ml/min/kg) and steady-state volume of distribution (229.9 vs. 603.1 ml/kg), while mono-PEG-sCT showed a prolonged elimination half-life (189.1 min vs. 59.8 min) compared with unmodified sCT.",Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145145/),[ml] / [kg],229.9,61677,DB00017,Salmon Calcitonin
,11145145,steady-state volume of distribution,"Di-PEG-sCT exhibited significantly reduced systemic clearance (2.3 vs. 11.1 ml/min/kg) and steady-state volume of distribution (229.9 vs. 603.1 ml/kg), while mono-PEG-sCT showed a prolonged elimination half-life (189.1 min vs. 59.8 min) compared with unmodified sCT.",Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145145/),[ml] / [kg],603.1,61678,DB00017,Salmon Calcitonin
,11145145,elimination half-life,"Di-PEG-sCT exhibited significantly reduced systemic clearance (2.3 vs. 11.1 ml/min/kg) and steady-state volume of distribution (229.9 vs. 603.1 ml/kg), while mono-PEG-sCT showed a prolonged elimination half-life (189.1 min vs. 59.8 min) compared with unmodified sCT.",Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145145/),min,189.1,61679,DB00017,Salmon Calcitonin
,11145145,elimination half-life,"Di-PEG-sCT exhibited significantly reduced systemic clearance (2.3 vs. 11.1 ml/min/kg) and steady-state volume of distribution (229.9 vs. 603.1 ml/kg), while mono-PEG-sCT showed a prolonged elimination half-life (189.1 min vs. 59.8 min) compared with unmodified sCT.",Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145145/),min,59.8,61680,DB00017,Salmon Calcitonin
,27480451,absolute bioavailability (F),"Notable sCT absolute bioavailability (F) values were: 5.5% from minispheres containing NaTDC (i.j), 17.3% with CG (i.c.) and 18.2% with C10 (i.c.).",Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480451/),%,5.5,66706,DB00017,Salmon Calcitonin
,27480451,absolute bioavailability (F),"Notable sCT absolute bioavailability (F) values were: 5.5% from minispheres containing NaTDC (i.j), 17.3% with CG (i.c.) and 18.2% with C10 (i.c.).",Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480451/),%,17.3,66707,DB00017,Salmon Calcitonin
,27480451,absolute bioavailability (F),"Notable sCT absolute bioavailability (F) values were: 5.5% from minispheres containing NaTDC (i.j), 17.3% with CG (i.c.) and 18.2% with C10 (i.c.).",Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480451/),%,18.2,66708,DB00017,Salmon Calcitonin
,27480451,F,A highly competitive F value of 2.7% was obtained for orally-administered sCT-minispheres containing CG (45μmol/kg) and coated with Eudragit®.,Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480451/),%,2.7,66709,DB00017,Salmon Calcitonin
,22579664,t(max),"5-CNAC absorption was rapid (t(max)=0.5h; C(max)=9.00 ± 2.74 μM (mean ± SD, n=6) and almost complete.",Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579664/),h,0.5,67136,DB00017,Salmon Calcitonin
,22579664,C(max),"5-CNAC absorption was rapid (t(max)=0.5h; C(max)=9.00 ± 2.74 μM (mean ± SD, n=6) and almost complete.",Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579664/),μM,9.00,67137,DB00017,Salmon Calcitonin
,22579664,elimination half-life (t(½)),The elimination half-life (t(½)) was 1.5 ± 1.1h.,Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579664/),h,1.5,67138,DB00017,Salmon Calcitonin
,22579664,C(max),Radioactivity in plasma reached C(max) (35.4 ± 7.9 μM) at 0.75 h and declined with a half-life of 13.9 ± 4.3h.,Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579664/),μM,35.4,67139,DB00017,Salmon Calcitonin
,22579664,half-life,Radioactivity in plasma reached C(max) (35.4 ± 7.9 μM) at 0.75 h and declined with a half-life of 13.9 ± 4.3h.,Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579664/),h,13.9,67140,DB00017,Salmon Calcitonin
,10969448,detection limit,Serum salmon calcitonin concentrations were measured using a validated radioimmunoassay method with a detection limit of 15.0 pg/ml.,Relative bioavailability of salmon calcitonin given intramuscularly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969448/),[pg] / [ml],15.0,81847,DB00017,Salmon Calcitonin
,24252061,bioactivity,The bioactivity of sCT after formulation into liposomes was 52-55%.,Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24252061/),%,52-55,89034,DB00017,Salmon Calcitonin
,25460544,Bioavailability,Bioavailability of leuprolide following pulmonary administration was 75% higher compared to subcutaneously administered leuprolide.,Effect of protease inhibitors on pulmonary bioavailability of therapeutic proteins and peptides in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25460544/),%,75,100120,DB00017,Salmon Calcitonin
,19477256,absolute bioavailability,Nasal administration of Amioca/Carbopol 974P powders without heat treatment resulted in an absolute bioavailability in rabbits of 8.2+/-3.0% for insulin.,Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,8.2,102369,DB00017,Salmon Calcitonin
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,26.4,102370,DB00017,Salmon Calcitonin
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,36.5,102371,DB00017,Salmon Calcitonin
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,19.3,102372,DB00017,Salmon Calcitonin
,20946924,EC(50),"There were linear and exponential relationships between conjugate MW with potency and efficacy respectively, however the largest MW conjugate still retained 70% of E(max) and an EC(50) of 3.7nM.",PK/PD modelling of comb-shaped PEGylated salmon calcitonin conjugates of differing molecular weights. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20946924/),nM,3.7,103844,DB00017,Salmon Calcitonin
,10468025,in,"The average baseline intestinal pH was 6.1 +/- 0.2 (mean +/- SEM, n = 12).",Impact of regional intestinal pH modulation on absorption of peptide drugs: oral absorption studies of salmon calcitonin in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468025/),,6.1,144956,DB00017,Salmon Calcitonin
,25660067,mass median aerodynamic diameter (MMAD),The mass median aerodynamic diameter (MMAD) varied between 1.9 and 4.7 μm.,"Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660067/),μm,1.9 and 4.7,159773,DB00017,Salmon Calcitonin
,15907605,current,An average current of 0.43+/-0.01 mA was maintained during patch application.,In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),ma,0.43,161011,DB00017,Salmon Calcitonin
,15907605,infusion rate,Iontophoretic patches delivered SCT at an average infusion rate of 177.9+/-58.7 ng/(min kg) and an average steady state concentration of 7.58+/-1.35 ng/ml was achieved.,In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),[ng] / [kg·min],177.9,161012,DB00017,Salmon Calcitonin
,15907605,steady state concentration,Iontophoretic patches delivered SCT at an average infusion rate of 177.9+/-58.7 ng/(min kg) and an average steady state concentration of 7.58+/-1.35 ng/ml was achieved.,In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),[ng] / [ml],7.58,161013,DB00017,Salmon Calcitonin
,15907605,Clearance,"Clearance and half-life of SCT after IV administration were found to be 16.8+/-0.9 ml/(min kg) and 33.5+/-3.3 min, respectively.",In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),[ml] / [kg·min],16.8,161014,DB00017,Salmon Calcitonin
,15907605,half-life,"Clearance and half-life of SCT after IV administration were found to be 16.8+/-0.9 ml/(min kg) and 33.5+/-3.3 min, respectively.",In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907605/),min,33.5,161015,DB00017,Salmon Calcitonin
,8852361,area under the blood concentration-time curve (AUC),"The pharmacokinetic parameters of subcutaneous SCT (1.2 and 4.7 micrograms/kg) thus estimated were as follows: the area under the blood concentration-time curve (AUC) = 89 and 550 pg.hr/ml, and mean residence time (MRT) = 44 and 65 minutes, respectively, when the AUC for an intravenous SCT (1.2 micrograms/kg) = 160 pg.hr/ml and the MRT = 10 minutes.",A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852361/),[h·pg] / [ml],89,188909,DB00017,Salmon Calcitonin
,8852361,area under the blood concentration-time curve (AUC),"The pharmacokinetic parameters of subcutaneous SCT (1.2 and 4.7 micrograms/kg) thus estimated were as follows: the area under the blood concentration-time curve (AUC) = 89 and 550 pg.hr/ml, and mean residence time (MRT) = 44 and 65 minutes, respectively, when the AUC for an intravenous SCT (1.2 micrograms/kg) = 160 pg.hr/ml and the MRT = 10 minutes.",A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852361/),[h·pg] / [ml],550,188910,DB00017,Salmon Calcitonin
,8852361,mean residence time (MRT),"The pharmacokinetic parameters of subcutaneous SCT (1.2 and 4.7 micrograms/kg) thus estimated were as follows: the area under the blood concentration-time curve (AUC) = 89 and 550 pg.hr/ml, and mean residence time (MRT) = 44 and 65 minutes, respectively, when the AUC for an intravenous SCT (1.2 micrograms/kg) = 160 pg.hr/ml and the MRT = 10 minutes.",A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852361/),min,44,188911,DB00017,Salmon Calcitonin
,8852361,mean residence time (MRT),"The pharmacokinetic parameters of subcutaneous SCT (1.2 and 4.7 micrograms/kg) thus estimated were as follows: the area under the blood concentration-time curve (AUC) = 89 and 550 pg.hr/ml, and mean residence time (MRT) = 44 and 65 minutes, respectively, when the AUC for an intravenous SCT (1.2 micrograms/kg) = 160 pg.hr/ml and the MRT = 10 minutes.",A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852361/),min,65,188912,DB00017,Salmon Calcitonin
,8852361,AUC,"The pharmacokinetic parameters of subcutaneous SCT (1.2 and 4.7 micrograms/kg) thus estimated were as follows: the area under the blood concentration-time curve (AUC) = 89 and 550 pg.hr/ml, and mean residence time (MRT) = 44 and 65 minutes, respectively, when the AUC for an intravenous SCT (1.2 micrograms/kg) = 160 pg.hr/ml and the MRT = 10 minutes.",A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852361/),[h·pg] / [ml],160,188913,DB00017,Salmon Calcitonin
,8852361,MRT,"The pharmacokinetic parameters of subcutaneous SCT (1.2 and 4.7 micrograms/kg) thus estimated were as follows: the area under the blood concentration-time curve (AUC) = 89 and 550 pg.hr/ml, and mean residence time (MRT) = 44 and 65 minutes, respectively, when the AUC for an intravenous SCT (1.2 micrograms/kg) = 160 pg.hr/ml and the MRT = 10 minutes.",A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852361/),min,10,188914,DB00017,Salmon Calcitonin
,30597264,oral absolute bioavailability,"In vivo, the oral absolute bioavailability of sCT in CS-sCT/PR-NPs was 12.52 ± 1.83%, approximately 1.74-fold higher than that of the NPs not co-loaded with PR.","Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30597264/),%,12.52,199944,DB00017,Salmon Calcitonin
,20660294,half-life,"Findings include these: (1) the optimal calcitonin tablet dose is 0.8 mg; (2) 0.8 mg of oral calcitonin is rapidly absorbed, reaching maximum concentration in 15 to 30 minutes, and is eliminated from plasma with a short half-life-9 to 15 minutes; (3) the 0.8-mg tablet is more highly absorbed than the marketed nasal formulation, with biomarker levels indicating significantly greater efficacy in suppression of bone resorption; (4) drug absorption is increased with dosing at least 10 minutes before a meal rather than postprandially and also with 50 mL of water; (5) the optimal timing of dosing for osteoporosis therapy is in the evening to mitigate the circadian peak in bone resorption; and (6) the oral formulations of synthetic and recombinant calcitonin have similar pharmacokinetic and pharmacodynamic properties.",Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660294/),min,9 to 15,205129,DB00017,Salmon Calcitonin
,19371314,relative oral bioavailability,"The predose meal at 18.00 and 21.00 h significantly decreased relative oral bioavailability of sCT to 26% [95% confidence interval (CI) 0.09, 0.73 and 0.09, 0.75, P= 0.009 and P= 0.01].",Influence of food intake on the bioavailability and efficacy of oral calcitonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371314/),%,26,205255,DB00017,Salmon Calcitonin
,19371314,oral bioavailability,"The meal consumed 10 min after dosing decreased the oral bioavailability of sCT to 59% (95% CI 0.21, 1.68), although nonsignificant (P= 0.48).",Influence of food intake on the bioavailability and efficacy of oral calcitonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371314/),%,59,205256,DB00017,Salmon Calcitonin
,19371314,AUC,"This decreased bioavailability led to lower relative suppression of serum CTX-I, with an AUC of the 4-h efficacy response of -91%-x-hours for those receiving a meal at 18.00 h, compared with -238%-x-hours for fasting subjects.",Influence of food intake on the bioavailability and efficacy of oral calcitonin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371314/),%-·-hours,-91,205257,DB00017,Salmon Calcitonin
,64046,elimination half-life,There was a rapid distribution phase of ca. 12 minutes after intravenous injection then an elimination half-life of 1.1 hours.,Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/64046/),h,1.1,207284,DB00017,Salmon Calcitonin
,64046,volume of distribution,The volume of distribution was 11 litres.,Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/64046/),l,11,207285,DB00017,Salmon Calcitonin
,64046,invasion half-life,"The invasion half-life after intramuscular and subcutaneous administration was 12 and 11 minutes respectively and the elimination half-lives 1 and 1.5 hours, respectively.",Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/64046/),min,12,207286,DB00017,Salmon Calcitonin
,64046,invasion half-life,"The invasion half-life after intramuscular and subcutaneous administration was 12 and 11 minutes respectively and the elimination half-lives 1 and 1.5 hours, respectively.",Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/64046/),min,11,207287,DB00017,Salmon Calcitonin
,64046,elimination half-lives,"The invasion half-life after intramuscular and subcutaneous administration was 12 and 11 minutes respectively and the elimination half-lives 1 and 1.5 hours, respectively.",Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/64046/),h,1,207288,DB00017,Salmon Calcitonin
,64046,elimination half-lives,"The invasion half-life after intramuscular and subcutaneous administration was 12 and 11 minutes respectively and the elimination half-lives 1 and 1.5 hours, respectively.",Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/64046/),h,1.5,207289,DB00017,Salmon Calcitonin
,64046,bioavailability,The bioavailability of the intramuscular and subcutaneous forms was found to be 66 and 71% respectively when areas under their plasma concentration/time curves were compared with the intravenous area.,Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/64046/),%,66,207290,DB00017,Salmon Calcitonin
,64046,bioavailability,The bioavailability of the intramuscular and subcutaneous forms was found to be 66 and 71% respectively when areas under their plasma concentration/time curves were compared with the intravenous area.,Pharmacokinetic study with synthetic salmon calcitonin (Sandoz). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/64046/),%,71,207291,DB00017,Salmon Calcitonin
,14508623,absolute bioavailability,"The relative bioavailability of nasally administered 2 IU/kg of mono-PEG2K-sCT was approximately 4-fold higher than nasally administrated unmodified sCT, and the absolute bioavailability was approximately 91% of intravenously injected sCT in 8 hr.",Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508623/),%,91,210071,DB00017,Salmon Calcitonin
,22322897,relative bioavailability,"Data obtained from in vivo experiments provided evidence of significantly (P < 0.05) higher mean plasma concentrations of sCT, after inhalation of micelles compared to sCT solution, at 60 and 90 min, a significantly higher AUC (inf) and a relative bioavailability of 160 ± 55% when compared to plain sCT solution.",In vitro and in vivo characterisation of PEG-lipid-based micellar complexes of salmon calcitonin for pulmonary delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322897/),%,160,219304,DB00017,Salmon Calcitonin
,7957525,maximum concentration,"The maximum concentration in plasma was 225 pg.ml-1 (in the first sample at 15 min), whereas in SBF the mean peak of 84 pg.",Availability of synthetic salmon calcitonin in tissue fluid after a single intravenous dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957525/),[pg] / [ml],225,219483,DB00017,Salmon Calcitonin
,7957525,peak,"The maximum concentration in plasma was 225 pg.ml-1 (in the first sample at 15 min), whereas in SBF the mean peak of 84 pg.",Availability of synthetic salmon calcitonin in tissue fluid after a single intravenous dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957525/),pg,84,219484,DB00017,Salmon Calcitonin
,23075315,bioavailability,"In vivo, the sCT SLNs prepared with SA and TP exhibited the highest reduction of plasma Ca(2+) level (17.44 ± 3.68%) with a bioavailability of 13.01 ± 3.24%.",Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle-double emulsion method via the combined use of different solid lipids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23075315/),%,13.01,224809,DB00017,Salmon Calcitonin
,18023905,C(max),"Specifically, C(max) values increased on increasing PEG Mw, i.e., 78.1+/-21.1, 102.9+/-9.1, and 115.2+/-5.7 for 1, 2, 5 kDa, respectively, vs. 54.8+/-3.9 ng/mL for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),,78.1,225622,DB00017,Salmon Calcitonin
,18023905,C(max),"Specifically, C(max) values increased on increasing PEG Mw, i.e., 78.1+/-21.1, 102.9+/-9.1, and 115.2+/-5.7 for 1, 2, 5 kDa, respectively, vs. 54.8+/-3.9 ng/mL for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),[ng] / [ml],102.9,225623,DB00017,Salmon Calcitonin
,18023905,C(max),"Specifically, C(max) values increased on increasing PEG Mw, i.e., 78.1+/-21.1, 102.9+/-9.1, and 115.2+/-5.7 for 1, 2, 5 kDa, respectively, vs. 54.8+/-3.9 ng/mL for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),[ng] / [ml],115.2,225624,DB00017,Salmon Calcitonin
,18023905,C(max),"Specifically, C(max) values increased on increasing PEG Mw, i.e., 78.1+/-21.1, 102.9+/-9.1, and 115.2+/-5.7 for 1, 2, 5 kDa, respectively, vs. 54.8+/-3.9 ng/mL for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),[ng] / [ml],54.8,225625,DB00017,Salmon Calcitonin
,18023905,circulating t(1/2),"Their circulating t(1/2) values also increased to 53.9+/-6.0, 100.7+/-21.7, and 119.4+/-13.7 min, respectively, vs. 34.6+/-7.6 min for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),min,53.9,225626,DB00017,Salmon Calcitonin
,18023905,circulating t(1/2),"Their circulating t(1/2) values also increased to 53.9+/-6.0, 100.7+/-21.7, and 119.4+/-13.7 min, respectively, vs. 34.6+/-7.6 min for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),min,100.7,225627,DB00017,Salmon Calcitonin
,18023905,circulating t(1/2),"Their circulating t(1/2) values also increased to 53.9+/-6.0, 100.7+/-21.7, and 119.4+/-13.7 min, respectively, vs. 34.6+/-7.6 min for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),min,119.4,225628,DB00017,Salmon Calcitonin
,18023905,circulating t(1/2),"Their circulating t(1/2) values also increased to 53.9+/-6.0, 100.7+/-21.7, and 119.4+/-13.7 min, respectively, vs. 34.6+/-7.6 min for sCT.",Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18023905/),min,34.6,225629,DB00017,Salmon Calcitonin
,19055791,Cmax,"Morning and pre-dinner dosing led to comparable concentration of sCT of 45 pg/ml, whereas there was a tendency towards lower Cmax for the evening dosing having a mean of 24 pg/ml.",Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19055791/),[pg] / [ml],24,232950,DB00017,Salmon Calcitonin
,18288448,Inhaled flow rates,"Inhaled flow rates were similar, although not equal, 5.8 and approximately 9.8 l/min respectively for dry powder and liquid inhalations.",A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288448/),[l] / [min],5.8,235797,DB00017,Salmon Calcitonin
,18288448,Inhaled flow rates,"Inhaled flow rates were similar, although not equal, 5.8 and approximately 9.8 l/min respectively for dry powder and liquid inhalations.",A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288448/),[l] / [min],9.8,235798,DB00017,Salmon Calcitonin
,18288448,relative lung bioavailability,"Pharmacokinetic profiles and lung bioavailability relative to subcutaneous injection for all formulations were similar (not statistically significantly different p > 0.05), relative lung bioavailability ranged from 11% to 18%, estimates of relative bioavailability based on peripheral lung dose ranged from 20% to 33%.",A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288448/),%,11,235799,DB00017,Salmon Calcitonin
,18288448,relative lung bioavailability,"Pharmacokinetic profiles and lung bioavailability relative to subcutaneous injection for all formulations were similar (not statistically significantly different p > 0.05), relative lung bioavailability ranged from 11% to 18%, estimates of relative bioavailability based on peripheral lung dose ranged from 20% to 33%.",A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288448/),%,18,235800,DB00017,Salmon Calcitonin
,18288448,relative bioavailability,"Pharmacokinetic profiles and lung bioavailability relative to subcutaneous injection for all formulations were similar (not statistically significantly different p > 0.05), relative lung bioavailability ranged from 11% to 18%, estimates of relative bioavailability based on peripheral lung dose ranged from 20% to 33%.",A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288448/),%,20,235801,DB00017,Salmon Calcitonin
,18288448,relative bioavailability,"Pharmacokinetic profiles and lung bioavailability relative to subcutaneous injection for all formulations were similar (not statistically significantly different p > 0.05), relative lung bioavailability ranged from 11% to 18%, estimates of relative bioavailability based on peripheral lung dose ranged from 20% to 33%.",A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288448/),%,33,235802,DB00017,Salmon Calcitonin
,10962228,bioavailability (BA),"After SC administration, the absorption of sCT was rapid with bioavailability (BA) varying from 21.4 to 52.9%.","Regional oral absorption, hepatic first-pass effect, and non-linear disposition of salmon calcitonin in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10962228/),%,21.4 to 52.9,235871,DB00017,Salmon Calcitonin
,8058647,bioavailabilities,"Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively.",The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058647/),%,3.9,241506,DB00017,Salmon Calcitonin
,8058647,bioavailabilities,"Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively.",The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058647/),%,7.9,241507,DB00017,Salmon Calcitonin
,8058647,bioavailabilities,"Relative to the IM dose, the bioavailabilities of the IN formulations containing 0.5% STDHF were 3.9, 7.9, and 7.4%, respectively.",The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058647/),%,7.4,241508,DB00017,Salmon Calcitonin
,8058647,bioavailability,"The 200-IU commercial formulation resulted in serum levels above the limit of detection in only 5 of 10 patients, with an average bioavailability of 1.6%.",The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058647/),%,1.6,241509,DB00017,Salmon Calcitonin
,15338848,peak plasma concentrations,Mean peak plasma concentrations ranging from 51+/-51-110+/-59 pg/ml were observed 36-54 minutes after administration.,Pharmacokinetics of modified oral calcitonin product in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338848/),[pg] / [ml],51,243103,DB00017,Salmon Calcitonin
,15338848,peak plasma concentrations,Mean peak plasma concentrations ranging from 51+/-51-110+/-59 pg/ml were observed 36-54 minutes after administration.,Pharmacokinetics of modified oral calcitonin product in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338848/),[pg] / [ml],110,243104,DB00017,Salmon Calcitonin
,15338848,terminal elimination half-lives,Mean terminal elimination half-lives ranged from 54-76 minutes.,Pharmacokinetics of modified oral calcitonin product in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338848/),min,54-76,243105,DB00017,Salmon Calcitonin
,9406061,detection limit,The practical detection limit of SCT was 0.05 pg (15 amol)/50 microliters of sample and 1 pg/ml as the concentration.,A sandwich transfer enzyme immunoassay for salmon calcitonin: determination of the bioavailability of intranasal salmon calcitonin in human. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9406061/),pg,0.05,255009,DB00017,Salmon Calcitonin
,9406061,area under the blood concentration-time curve (AUC),"The pharmacokinetic parameters of the intranasal SCT (n = 6) thus estimated were as follows: the area under the blood concentration-time curve (AUC) 9400 +/- 5400 (SD) pg.h/ml, and the mean residence time (MRT) = 42 +/- 14 (SD) min, when the AUC for the intramuscular SCT (n = 3) = 5600 +/- 2000 (SD) pg.h/ml and the MRT = 39 +/- 19 (SD) min.",A sandwich transfer enzyme immunoassay for salmon calcitonin: determination of the bioavailability of intranasal salmon calcitonin in human. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9406061/),[h·pg] / [ml],9400,255010,DB00017,Salmon Calcitonin
,9406061,mean residence time (MRT),"The pharmacokinetic parameters of the intranasal SCT (n = 6) thus estimated were as follows: the area under the blood concentration-time curve (AUC) 9400 +/- 5400 (SD) pg.h/ml, and the mean residence time (MRT) = 42 +/- 14 (SD) min, when the AUC for the intramuscular SCT (n = 3) = 5600 +/- 2000 (SD) pg.h/ml and the MRT = 39 +/- 19 (SD) min.",A sandwich transfer enzyme immunoassay for salmon calcitonin: determination of the bioavailability of intranasal salmon calcitonin in human. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9406061/),min,42,255011,DB00017,Salmon Calcitonin
,9406061,AUC,"The pharmacokinetic parameters of the intranasal SCT (n = 6) thus estimated were as follows: the area under the blood concentration-time curve (AUC) 9400 +/- 5400 (SD) pg.h/ml, and the mean residence time (MRT) = 42 +/- 14 (SD) min, when the AUC for the intramuscular SCT (n = 3) = 5600 +/- 2000 (SD) pg.h/ml and the MRT = 39 +/- 19 (SD) min.",A sandwich transfer enzyme immunoassay for salmon calcitonin: determination of the bioavailability of intranasal salmon calcitonin in human. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9406061/),[h·pg] / [ml],5600,255012,DB00017,Salmon Calcitonin
,9406061,MRT,"The pharmacokinetic parameters of the intranasal SCT (n = 6) thus estimated were as follows: the area under the blood concentration-time curve (AUC) 9400 +/- 5400 (SD) pg.h/ml, and the mean residence time (MRT) = 42 +/- 14 (SD) min, when the AUC for the intramuscular SCT (n = 3) = 5600 +/- 2000 (SD) pg.h/ml and the MRT = 39 +/- 19 (SD) min.",A sandwich transfer enzyme immunoassay for salmon calcitonin: determination of the bioavailability of intranasal salmon calcitonin in human. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9406061/),min,39,255013,DB00017,Salmon Calcitonin
,9138100,AUCs,"The pharmacokinetic parameters measured for the doses (1.25, 5, and 20 U/rat) were as follows; the AUCs (pg.hr/ml) = 20.8, 89.0, and 189, and the MRTs (min) = 52, 54, and 45, respectively.",Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9138100/),[h·pg] / [ml],20.8,260573,DB00017,Salmon Calcitonin
,9138100,AUCs,"The pharmacokinetic parameters measured for the doses (1.25, 5, and 20 U/rat) were as follows; the AUCs (pg.hr/ml) = 20.8, 89.0, and 189, and the MRTs (min) = 52, 54, and 45, respectively.",Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9138100/),[h·pg] / [ml],89.0,260574,DB00017,Salmon Calcitonin
,9138100,AUCs,"The pharmacokinetic parameters measured for the doses (1.25, 5, and 20 U/rat) were as follows; the AUCs (pg.hr/ml) = 20.8, 89.0, and 189, and the MRTs (min) = 52, 54, and 45, respectively.",Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9138100/),[h·pg] / [ml],189,260575,DB00017,Salmon Calcitonin
,9138100,MRTs,"The pharmacokinetic parameters measured for the doses (1.25, 5, and 20 U/rat) were as follows; the AUCs (pg.hr/ml) = 20.8, 89.0, and 189, and the MRTs (min) = 52, 54, and 45, respectively.",Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9138100/),min,52,260576,DB00017,Salmon Calcitonin
,9138100,MRTs,"The pharmacokinetic parameters measured for the doses (1.25, 5, and 20 U/rat) were as follows; the AUCs (pg.hr/ml) = 20.8, 89.0, and 189, and the MRTs (min) = 52, 54, and 45, respectively.",Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9138100/),min,54,260577,DB00017,Salmon Calcitonin
,9138100,MRTs,"The pharmacokinetic parameters measured for the doses (1.25, 5, and 20 U/rat) were as follows; the AUCs (pg.hr/ml) = 20.8, 89.0, and 189, and the MRTs (min) = 52, 54, and 45, respectively.",Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9138100/),min,45,260578,DB00017,Salmon Calcitonin
,12523672,C(max),"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[ng] / [ml],75.1,270413,DB00017,Salmon Calcitonin
,12523672,Cls,"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[ml] / [min],20.7,270414,DB00017,Salmon Calcitonin
,12523672,Cls,"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),ml,637,270415,DB00017,Salmon Calcitonin
,12523672,Vss,"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[ml] / [min],20.7,270416,DB00017,Salmon Calcitonin
,12523672,Vss,"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),ml,637,270417,DB00017,Salmon Calcitonin
,12523672,AUC(0-inf),"Rabbits injected intravenously had C(max), Cls, Vss, and AUC(0-inf) values of 75.1 +/- 6.5 ng/mL, 20.7 +/- 3.3 mL/min, 637 +/- 141 mL, and 1925 +/- 237 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[min·ng] / [ml],1925,270418,DB00017,Salmon Calcitonin
,12523672,C(max) Cls,"Rabbits dosed via the buccal route had C(max) Cls, and AUC(0-400 min values of 4.6 +/- 1.6 ng/mL, 22.0 +/- 5.9 mL/min, and 842.9 +/- 209.7 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[ng] / [ml],4.6,270419,DB00017,Salmon Calcitonin
,12523672,AUC(0-400 min,"Rabbits dosed via the buccal route had C(max) Cls, and AUC(0-400 min values of 4.6 +/- 1.6 ng/mL, 22.0 +/- 5.9 mL/min, and 842.9 +/- 209.7 ng*min/mL, respectively.",Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),[min·ng] / [ml],842.9,270420,DB00017,Salmon Calcitonin
,12523672,relative bioavailability,The relative bioavailability for rabbits treated with the TFCs was 43.8 +/- 10.9% with a CV of 24.9%.,Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12523672/),%,43.8,270421,DB00017,Salmon Calcitonin
,8587058,F,"Following sc administration, F ranged from 11.2% to 23.1% and was linear.",Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587058/),%,11.2,271054,DB00017,Salmon Calcitonin
,8587058,F,"Following sc administration, F ranged from 11.2% to 23.1% and was linear.",Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587058/),%,23.1,271055,DB00017,Salmon Calcitonin
,8587058,minimum dose required for maximum calcium lowering (Dmin/max),Serum calcium lowering was nonlinear and saturable after sc administration with the minimum dose required for maximum calcium lowering (Dmin/max) equal to 10.2 ng and a maximal response of 426.8 mg min/dL.,Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587058/),ng,10.2,271056,DB00017,Salmon Calcitonin
,8587058,maximal response,Serum calcium lowering was nonlinear and saturable after sc administration with the minimum dose required for maximum calcium lowering (Dmin/max) equal to 10.2 ng and a maximal response of 426.8 mg min/dL.,Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587058/),[mg·min] / [dl],426.8,271057,DB00017,Salmon Calcitonin
,8587058,absolute Fs,"Using Dmin/max as the reference dose, absolute Fs were recalculated using PD response after id. administration of 1 and 2 mg of rsCT and were 0.040% and 0.029%, respectively.",Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587058/),%,0.040,271058,DB00017,Salmon Calcitonin
,8587058,absolute Fs,"Using Dmin/max as the reference dose, absolute Fs were recalculated using PD response after id. administration of 1 and 2 mg of rsCT and were 0.040% and 0.029%, respectively.",Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8587058/),%,0.029,271059,DB00017,Salmon Calcitonin
